Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB5285 in Healthy Study Participants
NCT07286682Phase 1Active, not recruiting
- Sponsor
- UCB
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of galvokimig (8 cohorts), sponsored by UCB. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Incidence of Treatment-Emergent Serious Adverse Events. Started Dec 2025; status: active, not recruiting.
02
Drugs
galvokimig
Beyond the preview
Go deeper on NCT07286682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286682.